Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

October 12, 2017: By Jon Swedien

AlconAlcon announced Sept. 29 that its AcrySof intraocular lenses (IOLs) have been implanted more than 100 million times.

In celebration, Alcon launched its “100 Million Moments Made” campaign, which includes resources designed to showcase the accomplishment in markets around the globe, the Fort Worth, Texas, company said.

The first recorded implantation of an AcrySof IOL was in the UK in 1990. Since then, the platform has grown to include solutions for correcting astigmatism (AcrySof IQ Toric) and presbyopia (AcrySof IQ ReSTOR and PanOptix), Alcon said.

The AcrySof family of IOLs includes brands available in approximately 120 markets: AcrySof IQ, AcrySof IQ Toric, AcrySof IQ ReSTOR, AcrySof IQ ReSTOR Toric, AcrySof IQ PanOptix, and AcrySof IQ PanOptix Toric.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022